Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?

Abstract

Get full access to this article

View all access options for this article.

References

Brunner HR , Laragh JH , Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.

Brunner HR , Sealey JE , Laragh JH Renin as a risk factor in essential hypertension: more evidence. Am J Med 1973;55:295-302.

Dzau V. , Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121: 1244-63.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med 1987;316:1429-35.

McMurray JJ , Ostergren J. , Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.

McMurray J. , Pitt B. , Latini R. et al. Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.

Parving HH , Persson F. , Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy . N Engl J Med 2008;358:2433-46.

Yusuf S. , Teo KK , Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59